FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Nur für Forschungszwecke. Vollständige Erklärung →

Peptidebibliothek

5-Amino-1MQ

5-Amino-1-Methylquinolinium

Weight Loss & Metabolic

5-Amino-1MQ (5-amino-1-methylquinolinium) is a small molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that regulates cellular energy metabolism and is upregulated in white adipose tissue of obese individuals. By blocking NNMT, it increases intracellular NAD+ and SAM (S-adenosyl methionine) concentrations, shifting fat cells from storage toward energy expenditure. It is primarily researched as an oral metabolic modulator for obesity, metabolic syndrome, and cellular energy optimization.

Wirkmechanismus

Small molecule inhibitor of NNMT. Increases cellular NAD+ and SAM levels, activating SIRT1-dependent energy expenditure pathways.

Forschungsprotokolle

Nur für Forschungszwecke. Keine medizinische Beratung.

Research protocols use 50-150mg orally once daily. Often taken with food.

Forschungsnotizen

Clinical Research Status

5-Amino-1MQ is in preclinical development with published in vitro and animal model data but has not yet entered formal human clinical trials. Research is primarily based on studies from the University of Texas Health Science Center demonstrating its effects on adipocyte differentiation and metabolic pathways. The compound is available through research chemical suppliers and compounding pharmacies, though it lacks regulatory approval for any therapeutic indication.

Key Published Findings

Studies in diet-induced obesity mouse models showed that 5-Amino-1MQ treatment reduced body weight by approximately 7% over 11 days without affecting food intake or causing lean mass loss. In vitro research demonstrated that NNMT inhibition with 5-Amino-1MQ reduced lipid accumulation in differentiating adipocytes and increased intracellular NAD+ levels by 2-fold. The compound has been shown to shrink existing fat cells, prevent new fat cell maturation, and increase the activity of sirtuin-dependent metabolic pathways through NAD+ elevation.

Safety Profile

Preclinical toxicity data suggests 5-Amino-1MQ is well-tolerated in animal models at effective doses without significant organ toxicity or behavioral changes. As a relatively new research compound without human trial data, the long-term safety profile in humans remains uncharacterized. Users in the research community have self-reported generally mild side effects at doses of 50-150mg daily, though systematic adverse event data is absent.

Drug Interactions & Contraindications

Theoretical interactions exist with other compounds that affect methyl donor metabolism, including SAM-e supplements and medications metabolized by methyltransferase enzymes. Given its mechanism of increasing intracellular NAD+, concurrent use with NAD+ precursors (NMN, NR) may produce additive effects that are not yet characterized for safety. Individuals with hormone-sensitive conditions should exercise caution, as NNMT plays roles in estrogen and catecholamine metabolism.

Comparison to Related Compounds

Unlike traditional fat loss compounds that work through appetite suppression or thermogenesis (DNP, clenbuterol), 5-Amino-1MQ targets the metabolic programming of fat cells themselves through epigenetic regulation. Other NNMT inhibitors exist in research (methylquinolinium analogs), but 5-Amino-1MQ is the most characterized and commercially available for research purposes. Its mechanism of simultaneously increasing NAD+ and SAM makes it mechanistically distinct from direct NAD+ precursors like NMN, which do not address NNMT-mediated metabolic dysregulation.

Community Observations

Users typically report subtle but measurable changes in body composition over 4-8 weeks at oral doses of 50-150mg daily, with fat loss concentrated in visceral and stubborn subcutaneous depots. The compound is frequently stacked with other metabolic agents and exercise programs, making isolated effects difficult to assess in anecdotal reports. The research community notes that 5-Amino-1MQ appears to work best as a recomposition agent rather than a dramatic weight loss compound, and effects seem more pronounced in individuals with higher baseline body fat percentages.

Halbwertszeit

~2-3 hours (oral)

Rekonstitution

N/A (oral capsule form)

Lagerung

Lyophilisiert

Room temperature. Protect from moisture and light.

Rekonstituierter

N/A (oral form)

Rechtsstatus USA

Research chemical (not FDA-approved)

Auch bekannt als

5-Amino-1-Methylquinolinium

Häufig gestellte Fragen

Was ist 5-Amino-1MQ?

5-Amino-1MQ (5-amino-1-methylquinolinium) is a small molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that regulates cellular energy metabolism and is upregulated in white adipose tissue of obese individuals. By blocking NNMT, it increases intracellular NAD+ and SAM (S-adenosyl methionine) concentrations, shifting fat cells from storage toward energy expenditure. It is primarily researched as an oral metabolic modulator for obesity, metabolic syndrome, and cellular energy optimization.

Wie wirkt 5-Amino-1MQ?

Small molecule inhibitor of NNMT. Increases cellular NAD+ and SAM levels, activating SIRT1-dependent energy expenditure pathways.

Wie ist der regulatorische Status von 5-Amino-1MQ in den USA?

Research chemical (not FDA-approved)

Wie lang ist die Halbwertszeit von 5-Amino-1MQ?

~2-3 hours (oral)

Wie wird 5-Amino-1MQ noch genannt?

5-Amino-1-Methylquinolinium

Peptide Contacts bietet wissenschaftliche Zusammenfassungen für informationstechnische Zwecke an. Wir stellen keine Dokumentationen von Anbietern, keine Host- und keine Vertriebsdienstleistungen zur Verfügung und unterstützen keine Anbieter in irgendeiner Weise. Alle Zertifikate der Analyse, GMP-Zertifikate und Kommunikationen mit Anbietern müssen direkt vom Käufer angefordert und überprüft werden. Alles auf dieser Plattform stellt weder rechtliche, medizinische noch berufsmäßige Beratung dar. Nutzer sind allein verantwortlich für die Überprüfung der Anbieterzertifikate und das Gewährleisten des Einhaltens aller anwendbaren lokalen, zuständigen und federalen Gesetze beim Kauf von Forschungschemikalien. Die Nutzung dieser Plattform bedeutet die Annahme volles persönlichen Verantwortlichkeitsbewusstseins.

Ganze Erklärung lesen